Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension
Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss
Objective: To describe a case of proven Hashimoto Encephalopathy presenting with oromandibular dystonia (OMD) and orofacial dyskinesias (OFD) Background: Neurologic manifestations of Hashimoto’s Encephalopathy (HE)…Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To investigate the effect of the metabotropic glutamate 4 (mGlu4) positive allosteric modulator (PAM) ADX-88178 on parkinsonism, dyskinesia and psychosis-like behaviours (PLBs) in the…COPS: Continuous Observation of Parkinsonian Symptoms – A prospective data acquisition study using wearable accelerometery
Objective: To investigate the continuous and objective assessment of motor symptom severity in Parkinson’s Disease (PD) in everyday life. Background: Treatment adjustments in PD patients…Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset
Objective: To determine the effect of the serotonin 2A/2C (5-HT2A/2C) receptor inverse agonist nelotanserin on dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: Nelotanserin is a…Dopamine Receptor Gene Polymorphism in L-Dopa Induced Dyskinesia- A Study from Eastern India
Objective: We intended to find the frequency of Single Nucleotide Polymorphism (SNP) rs6280 in DRD3 gene in PD patients with and without Levodopa Induced Dyskinesia…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia
Objective: To determine the distribution and density of metabotropic glutamate 2 (mGlu2) receptors in the motor loop of the basal ganglia in 6-hydroxydopamine (6-OHDA)-lesioned rats…Impact of culture on Impulse control disorders and correlation with levodopa-induced dyskinesia in Parkinson’s disease in Egypt .
Objective: to study the impact of culture on the categories of impulse control disorders ( ICD ) in PD and its association with levodopa-induced dyskinesia…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 44
- Next Page »